284 related articles for article (PubMed ID: 34067494)
1. An Update on Pituitary Neuroendocrine Tumors Leading to Acromegaly and Gigantism.
Asa SL; Ezzat S
J Clin Med; 2021 May; 10(11):. PubMed ID: 34067494
[TBL] [Abstract][Full Text] [Related]
2. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.
Asa SL; Mete O; Riddle ND; Perry A
Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858
[TBL] [Abstract][Full Text] [Related]
3. The Clinicopathological Spectrum of Acromegaly.
Akirov A; Asa SL; Amer L; Shimon I; Ezzat S
J Clin Med; 2019 Nov; 8(11):. PubMed ID: 31766255
[TBL] [Abstract][Full Text] [Related]
4. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
[TBL] [Abstract][Full Text] [Related]
5. Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL; Mete O; Perry A; Osamura RY
Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
[TBL] [Abstract][Full Text] [Related]
6. Ectopic secretion of growth hormone-releasing hormone (GHRH) in neuroendocrine tumors: relevant clinical aspects.
Doga M; Bonadonna S; Burattin A; Giustina A
Ann Oncol; 2001; 12 Suppl 2():S89-94. PubMed ID: 11762359
[TBL] [Abstract][Full Text] [Related]
7. Acromegaly and somatotroph hyperplasia with adenomatous transformation due to pituitary metastasis of a growth hormone-releasing hormone-secreting pulmonary endocrine carcinoma.
Nasr C; Mason A; Mayberg M; Staugaitis SM; Asa SL
J Clin Endocrinol Metab; 2006 Dec; 91(12):4776-80. PubMed ID: 16968791
[TBL] [Abstract][Full Text] [Related]
8. Prolactin and Growth Hormone Signaling and Interlink Focused on the Mammosomatotroph Paradigm: A Comprehensive Review of the Literature.
Araujo-Castro M; Marazuela M; Puig-Domingo M; Biagetti B
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762304
[TBL] [Abstract][Full Text] [Related]
9. The clinical presentation of PIT1 positive pituitary neuroendocrine tumor immunonegative for growth hormone, prolactin, and thyroid stimulating hormone with analysis of clinical and immunostaining dissociation.
Hong S; Shinya Y; Trejo-Lopez JA; Gruber LM; Erickson D; Bendok BR; Chaichana KL; Atkinson JL; Marino MJ; Donaldson AM; Stokken JK; Westphal SA; Chang AY; Samson SL; Choby GW; Van Gompel JJ
Clin Neurol Neurosurg; 2024 Jan; 236():108075. PubMed ID: 38056042
[TBL] [Abstract][Full Text] [Related]
10. Cytokeratin 8/18-negative somatotroph pituitary neuroendocrine tumours (PitNETs, adenomas) show variable morphological features and do not represent a clinicopathologically distinct entity.
Soukup J; Cesak T; Hornychova H; Manethova M; Michnova L; Netuka D; Vitovcova B; Cap J; Ryska A; Gabalec F
Histopathology; 2021 Sep; 79(3):406-415. PubMed ID: 33738859
[TBL] [Abstract][Full Text] [Related]
11. Pathology of excessive production of growth hormone.
Scheithauer BW; Kovacs K; Randall RV; Horvath E; Laws ER
Clin Endocrinol Metab; 1986 Aug; 15(3):655-81. PubMed ID: 3095005
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
Gola M; Doga M; Bonadonna S; Mazziotti G; Vescovi PP; Giustina A
Pituitary; 2006; 9(3):221-9. PubMed ID: 17036195
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone (GH) and prolactin (PRL) gene expression and immunoreactivity in GH- and PRL-producing human pituitary adenomas.
Li J; Stefaneanu L; Kovacs K; Horvath E; Smyth HS
Virchows Arch A Pathol Anat Histopathol; 1993; 422(3):193-201. PubMed ID: 8493775
[TBL] [Abstract][Full Text] [Related]
14. Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features.
Dottermusch M; Ryba A; Ricklefs FL; Flitsch J; Schmid S; Glatzel M; Saeger W; Neumann JE; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):16. PubMed ID: 38228887
[TBL] [Abstract][Full Text] [Related]
15. [New pathological classification and clinical implications of pituitary neuroendocrine tumors of the 2022 WHO version].
Xie J; Wu ZB
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(47):3723-3726. PubMed ID: 36517420
[TBL] [Abstract][Full Text] [Related]
16. A clinicomorphological study of pituitary tumors associated with the clinical syndrome of acromegaly.
Andreeva M; Georgiev T; Bosadjieva E; Karagiosov L; Karagiosov K; Tomova A; Matrosov P; Kirilov G; Diankov L; Christova T
Exp Clin Endocrinol; 1991; 98(3):223-7. PubMed ID: 1778242
[TBL] [Abstract][Full Text] [Related]
17. Hormone secretion in vitro by plurihormonal pituitary adenomas of the acidophil cell line.
Asa SL; Kovacs K; Horvath E; Singer W; Smyth HS
J Clin Endocrinol Metab; 1992 Jul; 75(1):68-75. PubMed ID: 1352308
[TBL] [Abstract][Full Text] [Related]
18. Plurihormonal Pituitary Neuroendocrine Tumors: Clinical Relevance of Immunohistochemical Analysis.
Dumitriu-Stan RI; Burcea IF; Dobre R; Nastase VN; Ceausu RA; Raica M; Poiana C
Diagnostics (Basel); 2024 Jan; 14(2):. PubMed ID: 38248047
[TBL] [Abstract][Full Text] [Related]
19. [Plurihormonal PIT1-lineage pituitary neuroendocrine tumors: a clinicopathological study].
Duan ZJ; Feng J; Zhao HQ; Wang HD; Gui QP; Zhang XF; Ma Z; Hu ZJ; Xiang L; Qi XL
Zhonghua Bing Li Xue Za Zhi; 2023 Oct; 52(10):1017-1024. PubMed ID: 37805393
[No Abstract] [Full Text] [Related]
20. Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature.
Chinezu L; Vasiljevic A; Trouillas J; Lapoirie M; Jouanneau E; Raverot G
Eur J Endocrinol; 2017 Feb; 176(2):195-201. PubMed ID: 27913611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
